Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Subjects will receive either 5, 10 or 20 mcg of the vaccine |
|
| 2 | Placebo Comparator | Subjects will receive placebo control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GBS glycoconjugate vaccine | Biological | Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination. |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the safety and tolerability of an intramuscular GBS conjugate vaccine | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| To study the magnitude and durability of GBS-specific antibody responses over 12 months. | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Vaccines | Novartis Vaccines | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute for Pharmacokinetic and Analytical Studies I.P.A.S. | Ligornetto | Ligornetto | 6853 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Biological | Subjects will receive one dose of placebo |
|
| ID | Term |
|---|---|
| D020275 | Guillain-Barre Syndrome |
| D004194 | Disease |
| ID | Term |
|---|---|
| D011129 | Polyradiculoneuropathy |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D011115 | Polyneuropathies |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided